Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.
Di Filippo M, Ferraro D, Ragonese P, Prosperini L, Maniscalco GT, Gallo A, Cavalla P, Lorefice L, Nociti V, Di Sabatino E, Clerico M, Guaschino C, Radaelli M, Fantozzi R, Buttari F, Laroni A, Gajofatto A, Calabrese M, Malucchi S, Paolicelli D, De Luca G, Tomassini V, Lanzillo R, Moccia M, Solaro C, Cocco E, Gasperini C, Tortorella C; RIREMS (Rising Researchers in MS) group. Di Filippo M, et al. Among authors: clerico m. J Neurol. 2024 Jan;271(1):24-31. doi: 10.1007/s00415-023-12034-0. Epub 2023 Nov 3. J Neurol. 2024. PMID: 37922069 Free PMC article.
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Ferrero B, Rivoiro C, Ferrero C, Picco E, Ripellino P, Viglietti D, Giuliani G, Montanari E, Clerico M; OPTIMS Study Group. Durelli L, et al. Among authors: clerico m. J Neurol. 2008 Sep;255(9):1315-23. doi: 10.1007/s00415-008-0879-6. Epub 2008 Sep 25. J Neurol. 2008. PMID: 18825438 Clinical Trial.
Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.
Lugaresi A, Florio C, Brescia-Morra V, Cottone S, Bellantonio P, Clerico M, Centonze D, Uccelli A, di Ioia M, De Luca G, Marcellusi A, Paolillo A; BRIDGE study group. Lugaresi A, et al. Among authors: clerico m. BMC Neurol. 2012 Mar 5;12:7. doi: 10.1186/1471-2377-12-7. BMC Neurol. 2012. PMID: 22390218 Free PMC article. Clinical Trial.
Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L. Clerico M, et al. JAMA Neurol. 2014 Aug;71(8):954-60. doi: 10.1001/jamaneurol.2014.1200. JAMA Neurol. 2014. PMID: 24977406 Clinical Trial.
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.
De Mercanti S, Rolla S, Cucci A, Bardina V, Cocco E, Vladic A, Soldo-Butkovic S, Habek M, Adamec I, Horakova D, Annovazzi P, Novelli F, Durelli L, Clerico M. De Mercanti S, et al. Among authors: clerico m. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 21;3(1):e194. doi: 10.1212/NXI.0000000000000194. eCollection 2016 Feb. Neurol Neuroimmunol Neuroinflamm. 2016. PMID: 26819963 Free PMC article.
Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study.
Lugaresi A, De Robertis F, Clerico M, Brescia Morra V, Centonze D, Borghesan S, Maniscalco GT; RIVER study group. Lugaresi A, et al. Among authors: clerico m. Expert Opin Drug Deliv. 2016 Jul;13(7):931-5. doi: 10.1517/17425247.2016.1148029. Epub 2016 Feb 24. Expert Opin Drug Deliv. 2016. PMID: 26909646
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, Marfia GA, Sormani MP, Capra R, Centonze D; Italian PML study group. Landi D, et al. Neurology. 2017 Mar 21;88(12):1144-1152. doi: 10.1212/WNL.0000000000003740. Epub 2017 Feb 22. Neurology. 2017. PMID: 28228569 Free article.
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study.
Laroni A, Signori A, Maniscalco GT, Lanzillo R, Russo CV, Binello E, Lo Fermo S, Repice A, Annovazzi P, Bonavita S, Clerico M, Baroncini D, Prosperini L, La Gioia S, Rossi S, Cocco E, Frau J, Torri Clerici V, Signoriello E, Sartori A, Zarbo IR, Rasia S, Cordioli C, Cerqua R, Di Sapio A, Lavorgna L, Pontecorvo S, Barrilà C, Saccà F, Frigeni B, Esposito S, Ippolito D, Gallo F, Sormani MP; iMUST group. Laroni A, et al. Among authors: clerico m. Neurology. 2017 Nov 28;89(22):2222-2229. doi: 10.1212/WNL.0000000000004686. Epub 2017 Nov 1. Neurology. 2017. PMID: 29093064 Free article.
195 results